Publications by authors named "Hilde Van Campenhout"
Article Synopsis
- Nivolumab is now an approved immunotherapy for adjuvant treatment in patients with completely resected stage III or IV melanoma, and the PRESERV MEL study seeks to evaluate its real-world effectiveness and safety in Belgium and Luxembourg.* -
- The study enrolled 152 patients over a 2-year period and includes both prospective and retrospective data, with key outcomes measured over a follow-up duration of at least 11.4 months.* -
- Results show that at 12 and 18 months, the relapse-free survival rates were 74.7% and 68.4%, indicating promising initial outcomes for patients treated with nivolumab.*
Background And Objectives: The cost effectiveness of pregabalin as an add-on to the standard treatment of Belgian patients with post-herpetic neuralgia (PHN) had been demonstrated in a previously published Markov model. The purpose of this study was to update that model with more recent cost data and clinical evidence, and reevaluate the cost effectiveness from the payer's perspective of add-on pregabalin in a wider set of NeP conditions.
Methods: The model, featuring 4-week cycles and a 1-year time horizon, consisted in four possible health states: mild, moderate or severe pain and withdrawn from therapy.
Objective: The objective of this study was to assess, in a real-world setting, the predictive validity (in terms of clinical outcome and treatment cost) of the voriconazole arm of a health-economic model applied in the Belgian reimbursement submission for use of voriconazole in the treatment of invasive aspergillosis.
Methods: A non-interventional study was designed to prospectively collect clinical response and direct costs data related to the treatment of invasive aspergillosis with voriconazole (oral, intravenous) in real-world practice. The outcomes of this study were compared with the inputs and outputs of the health-economic model.